Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Estimating Costs Associated with Disease Model States Using Generalized Linear Models: A Tutorial.

Zhou J. et al, (2023), Pharmacoeconomics

Long-term cardiovascular risks and statin treatment impact on socioeconomic inequalities: microsimulation model

Wu R. et al, (2023), British Journal of General Practice

Prediction Models for Individual-Level Healthcare Costs Associated with Cardiovascular Events in the UK.

Zhou J. et al, (2023), Pharmacoeconomics, 41, 547 - 559

A systematic review of the factors associated with suicide attempts among sexual-minority youth

Wang XX. et al, (2023), The European Journal of Psychiatry, 37, 72 - 83

Cost-effectiveness of endovascular thrombectomy with alteplase versus endovascular thrombectomy alone for acute ischemic stroke secondary to large vessel occlusion.

Ye Z. et al, (2023), CMAJ Open, 11, E443 - E450

Efficacy and safety of selegiline for the treatment of Parkinson's disease: A systematic review and meta-analysis.

Wang K. et al, (2023), Front Aging Neurosci, 15

CALIBRATING CARDIOVASCULAR DISEASE POLICY MODEL USING LARGE COHORT DATA

Wu R. et al, (2022), VALUE IN HEALTH, 25, S16 - S16

EXCESS ANNUAL HOSPITAL COSTS DUE TO CARDIOVASCULAR EVENTS IN A CONTEMPORARY UK POPULATION TO INFORM HEALTH TECHNOLOGY ASSESSMENTS

Zhou J. et al, (2022), VALUE IN HEALTH, 25, S12 - S12

Evaluation of rivaroxaban-, apixaban- and dabigatran-associated hemorrhagic events using the FDA-Adverse event reporting system (FAERS) database

Guo M. et al, (2021), International Journal of Clinical Pharmacy, 43, 1508 - 1515

A model of lifetime health outcomes in cardiovascular disease based on clinical trials and large cohorts

Wu R. et al, (2021), EUROPEAN HEART JOURNAL, 42, 3149 - 3149

Incorporating future unrelated medical costs in cost-effectiveness analysis in China.

Jiang S. et al, (2021), BMJ Glob Health, 6

Which Criteria are Considered and How are They Evaluated in Health Technology Assessments? A Review of Methodological Guidelines Used in Western and Asian Countries

Wang Y. et al, (2021), Applied Health Economics and Health Policy, 19, 281 - 304

Economic burden for Alzheimer’s disease in China from 2010 to 2050: a modelling study

Clay E. et al, (2019), Journal of Market Access & Health Policy, 7, 1667195 - 1667195

Systematic review of utility values used in the pharmacoeconomic evaluations for schizophrenia: implications on cost-effectiveness results

Zhou J. et al, (2019), Journal of Market Access & Health Policy, 7, 1648973 - 1648973

Include forthcoming?